CN119139546A

CN119139546A - Artificial prostate tissue induction composite material and preparation method thereof

Info

Publication number: CN119139546A
Application number: CN202411634423.9A
Authority: CN
Inventors: 任善成; 娄义浩云; 范志国
Original assignee: Second Affiliated Hospital Army Medical University
Current assignee: Second Affiliated Hospital Army Medical University
Priority date: 2024-11-15
Filing date: 2024-11-15
Publication date: 2024-12-17

Abstract

The invention discloses an artificial prostate tissue induction composite material and a preparation method thereof in the field of implant materials, wherein the composite material comprises an artificial prostate matrix and a cytokine coating, the artificial prostate matrix comprises peptide-metal composite polyether ether ketone fibers, DMAEMA-salt and methyl methacrylate, and the cytokine coating comprises aldehyde chitosan powder, methacrylic anhydride, collagen powder, TPO and BDNF solution. According to the invention, the artificial prostate basal body is prepared, and the coating containing the nerve cell trophic factors is coated on the surface of the artificial prostate basal body, so that the compatibility of the artificial prostate and human tissues can be improved, the inflammatory reaction caused by the artificial prostate is avoided, and simultaneously, the nerve growth nearby the prostate can be promoted by releasing the nerve cell trophic factors.

Description

Artificial prostate tissue induction composite material and preparation method thereof

Technical Field

The invention belongs to the technical field of implantation materials, and particularly relates to an artificial prostate tissue induction composite material and a preparation method thereof.

Background

An artificial prostate implant is a medical device for treating a prostate-related disease or performing a prostate replacement procedure. Its use is often associated with prostate cancer, prostatic hyperplasia or other prostate diseases. Common artificial prostate implant materials are prostate stents, which employ implants to support or fix the prostate tissue, commonly used to treat prostatic hyperplasia or other structural problems, and prostate substitutes, which may be used to maintain normal function of the urinary tract and urinary system after prostatectomy in some extreme cases. The biological material of artificial prostate is mainly used for replacing, supporting or treating related diseases of the prostate, and is required to have good biocompatibility, mechanical strength and long-term stability. Common biomaterials include Polytetrafluoroethylene (PTFE), which has excellent chemical stability and biocompatibility, is often used in the manufacture of stents or other implants, polyethylene (PE), which has high strength and wear resistance, is widely used in medical implants, especially in support devices or wrap materials, polylactic acid (PLA) and polyglycolic acid (PGA), which are biodegradable synthetic polymers, suitable for short-term implants, for temporary support structures, which are gradually absorbed by the body after implantation, silicone, which is often used in the manufacture of medical implants, such as devices for supporting or replacing the functions of the prostate part, because of its elasticity and biocompatibility, which is of limited flexibility, cannot be used in environments subject to high stresses, which cannot be degraded in biological environments, which can cause inflammatory reactions during long-term implantation, or which can cause local acidic environments, which can stimulate surrounding tissues, and which each of the different biomaterials has its unique advantages and limitations. In practice, it is often necessary to make a reasonable choice according to clinical needs, and composite or coating techniques are sometimes employed to optimize the performance of the implant.

Disclosure of Invention

Aiming at the situation, the invention adopts the following technical scheme that the invention provides an artificial prostate tissue induction composite material, which comprises an artificial prostate basal body and a cytokine coating:

Preferably, the artificial prostate matrix is prepared by curing a prostate matrix material, wherein the preparation raw materials of the artificial prostate matrix material comprise, by weight, 5-10 parts of peptide-metal composite polyether-ether-ketone fibers, 12-15 parts of 3- [ N, N-dimethyl- [2- (2-methylpropan-2-enoyloxy) ethyl ] ammonium ] propane-1-sulfonic acid inner salt (DMAEMA-salt) and 20-25 parts of methyl methacrylate;

Preferably, the cytokine coating is prepared by photocuring cytokine coating precursor solution, wherein the cytokine coating precursor solution is prepared from the following components, by weight, 5-8 parts of aldehyde chitosan powder, 14-18 parts of methacrylic anhydride, 3-5 parts of collagen powder, 0.8-1 part of 2,4, 6-trimethylbenzoyl-diphenyl phosphine oxide (TPO) and 5-6 parts of BDNF solution;

Preferably, the artificial prostate tissue inducing composite material further comprises a signal acquisition module, a signal control module and a treatment module;

the signal control module controls the treatment module to perform continuous discharge stimulation so as to regulate the sensation of the bladder urethra and relieve the condition of frequent urination and incontinence;

the invention also provides a preparation method of the artificial prostate tissue induction composite material, which specifically comprises the following steps:

S1, placing peptide-metal composite polyether-ether-ketone fibers in an ethanol solution, stirring at a speed of 200-250rpm, fully dispersing for 1-2 hours, adding DMAEMA-salt and methyl methacrylate into a reaction system, continuously stirring for 2-3 hours, and then distilling under reduced pressure to remove ethanol and deionized water to obtain an artificial prostate matrix solution;

S2, adding the artificial prostate matrix solution prepared in the step S1 into a sodium persulfate solution, regulating the pH value to 8.5, uniformly mixing, transferring into a prostate matrix mould, raising the reaction temperature to 40-50 ℃, curing for 3-5 hours, demoulding after curing, washing with deionized water, and vacuum drying to obtain an artificial prostate matrix;

S3, coating the cytokine coating precursor solution on the inner surface and the outer surface of the artificial prostate precursor prepared in the step S2, irradiating for 30-60S under blue-violet light, and curing the cytokine coating to obtain an artificial prostate tissue induction composite material;

preferably, in the step S1, the mass concentration of the peptide-metal composite polyether-ether-ketone fiber in an ethanol solution is 10-25g/L;

Preferably, in step S2, the mass fraction of sodium persulfate in the sodium persulfate solution is 10% -20%, and the addition volume of the sodium persulfate solution is 0.5% -1% of the volume of the artificial prostate basal body solution;

preferably, the preparation method of the peptide-metal composite polyether-ether-ketone fiber specifically comprises the following steps:

T1, placing the polyether-ether-ketone fibers in a beaker, sequentially placing acetone, absolute ethyl alcohol and deionized water in an ultrasonic cleaner for washing, wherein the power of the ultrasonic cleaner is 500W, the cleaning time is 30-60min, removing impurities on the surfaces of the polyether-ether-ketone fibers, and drying to obtain pretreated polyether-ether-ketone fibers;

T2, soaking the pretreated polyether-ether-ketone fibers prepared in the step T1 in concentrated sulfuric acid, carrying out ultrasonic treatment at 400-600W power for 3-5min, filtering, taking solids, washing with acetone and deionized water in sequence, and drying to obtain sulfonated polyether-ether-ketone fibers;

And T3, placing the sulfonated polyether-ether-ketone fiber prepared in the step T2 into methylene dichloride, adding aluminum chloride for mixing, slowly adding succinic anhydride/methylene dichloride solution, introducing nitrogen into a reaction system, raising the temperature to 40-45 ℃ under the nitrogen atmosphere, stirring at the speed of 150rpm, carrying out reflux reaction for 4-6h, cooling the reaction system to room temperature, carrying out ultrasonic cleaning with sodium hydroxide solution, hydrochloric acid solution, deionized water and acetone in sequence under the power of 500W, and drying to obtain the modified polyether-ether-ketone fiber;

preferably, in the step T3, the mass concentration of the sulfonated polyether-ether-ketone fibers in methylene dichloride is 25-50g/L;

Preferably, in the step T3, the mass concentration of the succinic anhydride in the methylene dichloride is 0.065-0.1g/mL, and the mass ratio of the sulfonated polyether-ether-ketone fiber to the succinic anhydride is 2:1.5-2;

preferably, in the step T3, the mass ratio of the sulfonated polyether-ether-ketone fibers to the anhydrous aluminum chloride is 1:1-1.2;

Dispersing the modified polyether-ether-ketone fiber prepared in the step T3 in DMF, adding zinc chloride, uniformly mixing, adding a dopamine solution, stirring at the speed of 300-3500rpm, adding p-toluenesulfonic acid, raising the reaction temperature to 90-100 ℃, continuously stirring and reacting for 4-6 hours, distilling under reduced pressure to remove the solvent, preparing a Tris buffer solution with the pH value of 8.5-9.0, adding the Tris buffer solution into a reaction system, placing the Tris buffer solution into the reaction system at the temperature of 37 ℃, stirring and reacting for 20-28 hours at the speed of 500-600rpn, filtering, washing the precipitate with deionized water, absolute ethyl alcohol and acetone, and vacuum drying to obtain the polydopamine modified polyether-ether-ketone fiber;

Preferably, in the step T4, the mass concentration of the modified polyether ether ketone fiber in DMF is 10-15g/L;

preferably, in the step T4, the addition mass of the zinc chloride is 10% -20% of the mass of the modified polyether-ether-ketone fiber;

Preferably, in the step T4, the dopamine solution is a solution of dopamine dissolved in an ethanol water solution (V _Ethanol:V_{Water and its preparation method} =1:3), the mass concentration of the dopamine in the ethanol water solution is 40-60g/L, and the mass ratio of the dopamine to the modified polyether ether ketone fibers is 1:0.7-0.9;

preferably, in the step T4, the adding mass of the p-toluenesulfonic acid is 1% -2% of the mass of the modified polyether-ether-ketone fiber;

Preferably, in step T4, the ratio of the added volume of the Tris buffer solution to the volume of DMF solvent is 1-1.5:1;

Dissolving L-histidine in tetrahydrofuran, adding triphosgene under nitrogen atmosphere, raising the reaction temperature to 50-60 ℃, stirring for reaction for 1-2h, cooling the reaction system, adding the cooled reaction system into n-hexane for sedimentation treatment, filtering, taking precipitate, recrystallizing with ethyl acetate, and drying to obtain histidine-NCA;

preferably, in the step T5, the mass concentration of the L-histidine in tetrahydrofuran is 60-80g/L;

Preferably, in step T5, the mass ratio between the L-histidine and the triphosgene is 1:1.2-1.5;

T6, placing the polydopamine modified polyether-ether-ketone fiber prepared in the step T4 into dichloromethane, adding histidine-NCA prepared in the step T5, placing in argon atmosphere, stirring at 400-600rpm for reaction, filtering to remove solvent after 24-36h, washing with DMF and dichloromethane, and vacuum drying to obtain the polypeptide composite polyether-ether-ketone fiber;

Preferably, in the step T6, the mass concentration of the polydopamine modified polyether-ether-ketone fiber in dichloromethane is 40-50g/L;

Preferably, in the step T6, the mass ratio between the polydopamine modified polyether ether ketone fiber and the histidine-NCA is 1:3-4;

T7, dispersing the polypeptide composite polyether-ether-ketone fiber prepared in the step T6 in absolute ethyl alcohol, adding zinc chloride, stirring at the speed of 400-500rpm under the condition of room temperature, reacting for 4-6 hours, dialyzing with 3500Da dialysis bag with Tris buffer solution for 24 hours, and freeze-drying to obtain the peptide-metal composite polyether-ether-ketone fiber;

preferably, in the step T7, the mass concentration of the polypeptide composite polyether-ether-ketone fiber in the absolute ethyl alcohol is 10-15g/L;

Preferably, in the step T7, the addition mass of the zinc chloride is 15% -20% of the mass of the polypeptide composite polyether-ether-ketone fiber;

preferably, the preparation method of the cytokine coating precursor solution specifically comprises the following steps:

K1, placing chitosan into deionized water, regulating the pH to 5.5-6.5, completely dissolving the chitosan, adding sodium periodate, uniformly mixing, placing the mixture under the condition of room temperature, performing dark reaction for 6-8 hours, adding ascorbic acid to terminate the reaction until the color of a reaction system is not changed, and performing freeze drying after the reaction is completed to obtain the hydroformylation chitosan;

Preferably, in the step K1, the mass concentration of the chitosan in deionized water is 15-25g/L;

preferably, in the step K1, the mass ratio of the chitosan to the sodium periodate is 10:8-9;

K2, dispersing the formylated chitosan prepared in the step K1 in a DMF solvent, adding hydrogen peroxide, stirring at a speed of 150rpm until the formylated chitosan is completely dissolved, adding methacrylic anhydride, adjusting the pH of a reaction system to 8-9, placing in an ice water bath environment, continuously stirring for reaction for 12 hours, placing in a dialysis bag after the reaction is completed, dialyzing for 2d by deionized water, and freeze-drying to obtain modified chitosan powder;

Preferably, in the step K2, the mass concentration of the aldehyde chitosan in the DMF solvent is 40-60g/L;

Preferably, in the step K2, the volume ratio of the hydrogen peroxide to the DMF solvent is 1-1.5:1;

k3, dissolving collagen in NaCl aqueous solution, adding the modified chitosan powder prepared in the step K2, stirring for reaction at the speed of 200rpm, adding 2,4, 6-trimethylbenzoyl-diphenyl phosphine oxide, placing the mixture under the condition of 4 ℃ for uniform mixing, adding BDNF solution, and continuously stirring for 2-3 hours to obtain cytokine coating precursor solution;

Preferably, in the step K3, the mass fraction of the NaCl aqueous solution is 1% -1.2%, and the mass concentration of the collagen in the NaCl aqueous solution is 20-25g/L;

Preferably, in the step K3, the BDNF solution is a solution of BDNF dissolved in deionized water, and the mass concentration is 10 mug/mL.

The beneficial effects obtained by the invention are as follows:

The invention provides an artificial prostate tissue induction composite material and a preparation method thereof, wherein the artificial prostate matrix is prepared, and the surface of the artificial prostate matrix is coated with a coating containing nerve cell trophic factors, so that the compatibility of the artificial prostate and human tissue can be improved, inflammatory reaction caused by the artificial prostate is avoided, and simultaneously, the nerve growth nearby the prostate can be promoted by releasing the nerve cell trophic factors; the modified polyether-ether-ketone fiber is modified by carboxylation, the reaction capacity with dopamine hydroxyl groups is increased, the adhesive capacity of polydopamine on the surface of the polyether-ether-ketone fiber is increased, amino groups are introduced to the surface of the polyether-ether-ketone fiber, and through the polymerization reaction of amino groups and histidine polypeptide, a peptide compound is formed, meanwhile imidazole groups on histidine can form a surface structure with high activity with zinc element, the mechanical strength and toughness of the artificial prostate-ketone fiber can be proved to have influence, and simultaneously, the rejection reaction between polyether-ether-ketone and human body can be overcome, and the invention uses EMA-specific amphiphile as one of the hydrophilic and anionic monomers, the invention relates to a method for preparing a cell factor coating, which can improve the antibacterial property of an artificial prostate matrix, has an anionic sulfonic group at the molecular end, can form electrostatic adsorption with a cationic group in chitosan in a coating solution, so as to improve the adhesiveness of the coating on the prostate matrix.

Drawings

FIG. 1 is an SEM image of the microstructure of an artificial prostate substrate prepared in example 1;

FIG. 2 is a schematic structural diagram of the artificial prostate tissue inducing composite material prepared in example 1, wherein 1 is an artificial prostate matrix and 2 is a cytokine coating;

FIG. 3 is a graph showing the results of mechanical properties of the prostatectomy matrices prepared in examples 1-3 and comparative examples 1-3;

FIG. 4 is a graph showing the release performance results of BDNF of the artificial prostate tissue inducing composite prepared in example 1 and comparative examples 1 to 4;

fig. 5 is a graph showing the long-term slow release effect of the artificial prostate tissue inducing composite material prepared in example 1 and comparative examples 1 and 3 of the present invention.

The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate the invention and together with the embodiments of the invention, serve to explain the invention.

Detailed Description

The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and all other embodiments obtained by those skilled in the art without making any inventive effort based on the embodiments of the present invention are within the scope of protection of the present invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the present application. The preferred methods and materials described herein are illustrative only and should not be construed as limiting the application.

The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials and experimental strains used in the following examples are commercially available unless otherwise specified.

Example 1

The embodiment provides an artificial prostate tissue induction composite material, which comprises an artificial prostate basal body and a cytokine coating;

the artificial prostate tissue induction composite material also comprises a signal acquisition module, a signal control module and a treatment module;

the artificial prostate matrix is prepared by solidifying a prostate matrix material, wherein the preparation raw materials of the artificial prostate matrix material comprise the following components in parts by weight of 5 parts of peptide-metal composite polyether-ether-ketone fiber, 12 parts of DMAEMA-salt and 20 parts of methyl methacrylate;

The preparation method of the peptide-metal composite polyether-ether-ketone fiber specifically comprises the following steps:

T1, placing the polyether-ether-ketone fibers in a beaker, sequentially placing acetone, absolute ethyl alcohol and deionized water in an ultrasonic cleaner for cleaning, wherein the power of the ultrasonic cleaner is 500W, the cleaning time is 30min, removing impurities on the surfaces of the polyether-ether-ketone fibers, and drying to obtain pretreated polyether-ether-ketone fibers;

T2, soaking the pretreated polyether-ether-ketone fibers prepared in the step T1 in concentrated sulfuric acid, carrying out ultrasonic treatment at 400W power for 3min, filtering, taking solids, washing with acetone and deionized water in sequence, and drying to obtain sulfonated polyether-ether-ketone fibers;

And T3, accurately weighing 2g of sulfonated polyether-ether-ketone fiber, placing the sulfonated polyether-ether-ketone fiber in 80mL of dichloromethane, accurately weighing 2g of anhydrous aluminum chloride, placing the anhydrous aluminum chloride in a reaction system, uniformly mixing, accurately weighing 1.5g of succinic anhydride, dissolving the anhydrous aluminum chloride in 20mL of dichloromethane, introducing nitrogen into the reaction system, slowly dropwise adding succinic anhydride/dichloromethane solution at the speed of 1mL/min, stirring at the speed of 150rpm under the nitrogen atmosphere at the temperature of 45 ℃, after the reflux reaction is carried out for 4 hours, cooling the reaction system to room temperature, sequentially carrying out ultrasonic cleaning by 5wt% of sodium hydroxide solution, 5wt% of hydrochloric acid solution, deionized water and acetone under the power of 500W, and carrying out vacuum drying at the temperature of 40 ℃ for 3 hours to obtain modified polyether-ether-ketone fiber;

And T4, accurately weighing 1g of the modified polyether-ether-ketone fiber prepared in the step T3, dispersing in 100mLDMF, accurately weighing 0.1g of zinc chloride, adding the zinc chloride into a reaction system, stirring for full dissolution, accurately weighing 0.8g of dopamine hydrochloride, dissolving in 20mL of ethanol water solution (V _Ethanol：V_{Water and its preparation method} =1:3), adding the solution into the reaction system, stirring at the speed of 300rpm, adding 0.01g of p-toluenesulfonic acid, raising the reaction temperature to 100 ℃, continuously stirring for 5h, distilling under reduced pressure to remove a solvent, preparing a Tris buffer solution with the pH of 8.5, taking 100mL of the Tris buffer solution, adding the 100mL of Tris buffer solution into the reaction system, stirring for 24h at the speed of 600: 600rpn, filtering, sequentially and repeatedly washing the precipitate with deionized water, absolute ethanol and acetone for three times, and drying in vacuum at the temperature of 40 ℃ for 12h to obtain the polydopamine modified polyether-ketone fiber;

T5, accurately weighing 15g of L-histidine, adding 250mL of tetrahydrofuran, vacuumizing until no bubble is generated, continuously introducing flowing nitrogen into a reaction system, stirring at 150rpm, adding 9g of triphosgene, uniformly mixing, raising the reaction temperature to 55 ℃, continuously stirring for reacting for 1h, adding 9g of triphosgene, continuously stirring for reacting for 1h, stopping adding after the reaction is gradually clarified, concentrating the reaction system to 20% of the original volume, adding pre-cooled n-hexane into the reaction system for sedimentation, filtering, collecting the sediment, dissolving with 50mL of ethyl acetate for recrystallization treatment, placing in a nitrogen environment, drying, and removing redundant solvent to obtain histidine-NCA;

T6, placing 0.5g of the polydopamine modified polyether-ether-ketone fiber prepared in the step T4 into a beaker, adding 10mL of dichloromethane, fully mixing, adding 1.5g of histidine-NCA prepared in the step T5, vacuumizing a reaction system, introducing argon, stirring and reacting for 36h at a speed of 400rpm under an argon atmosphere, performing suction filtration, removing dichloromethane, repeatedly washing for three times sequentially with DMF and dichloromethane, placing at 40 ℃, and performing vacuum drying for 12h to obtain the polypeptide composite polyether-ether-ketone fiber;

T7, dispersing 0.1g of the polypeptide composite polyether-ether-ketone fiber prepared in the step T6 in 10mL of absolute ethyl alcohol, accurately weighing 1g of zinc chloride, dissolving in 100mL of deionized water, adding 2mL of zinc chloride into a reaction system, stirring at a speed of 500rpm at room temperature, reacting for 5 hours, transferring the reaction system into a 3500Da dialysis bag, dialyzing with a Tris solution with a pH value of 7.6, and freeze-drying after 24 hours to obtain the peptide-metal composite polyether-ether-ketone fiber;

The cytokine coating is prepared by photocuring cytokine coating precursor solution, and the preparation raw materials of the cytokine coating precursor solution comprise, by weight, 8 parts of aldehyde chitosan powder, 14 parts of methacrylic anhydride, 5 parts of collagen powder, 0.8 part of TPO (thermoplastic polyolefin elastomer) and 6 parts of BDNF solution;

the preparation method of the cytokine coating precursor solution specifically comprises the following steps:

K1, accurately weighing 5g of chitosan, dispersing in 200mL of deionized water, regulating the pH of a reaction system to 5.5, completely dissolving the chitosan, adding 4g of sodium periodate, uniformly mixing, placing under the condition of room temperature, performing dark reaction for 8 hours, adding ascorbic acid to terminate the reaction until the color of the reaction system is not changed, dialyzing for 2d by using deionized water by using a dialysis bag with the retention amount of 3.5kDa after the reaction is completed, and freeze-drying to obtain the hydroformylation chitosan;

K2, dispersing 0.8g of the hydroformylation chitosan prepared in the step K1 in 20mL of DMF solvent, adding 20mL of 3wt% hydrogen peroxide solution, stirring at a speed of 150rpm until the hydroformylation chitosan is completely dissolved, adding 1.4mL of methacrylic anhydride, regulating the pH of a reaction system to 8, placing in an ice water bath environment, continuing stirring for reaction for 12h, placing in a dialysis bag with a cutoff of 3.5kDa, dialyzing for 2d with deionized water after the reaction is completed, and freeze-drying to obtain modified chitosan powder;

K3, dissolving 0.5g of collagen in 20mL of 1wt% NaCl aqueous solution, adding the modified chitosan powder prepared in the step K2, stirring for reaction at the speed of 200rpm, adding 0.08g of TPO, placing the mixture under the condition of 4 ℃ for uniform mixing, adding 0.6mL of 10 mug/mL BDNF solution, and continuing stirring for 2 hours to obtain a cytokine coating precursor solution;

the embodiment also provides an artificial prostate tissue inducing composite material, which comprises the following steps:

S1, placing 2g of the peptide-metal composite polyether-ether-ketone fiber in 30vol percent of 100mL of ethanol solution, performing ultrasonic treatment for 20min under the power of 500W to fully infiltrate the peptide-metal composite polyether-ether-ketone fiber in the ethanol solution, stirring at the speed of 200rpm, reacting for 2h, adding 4.8g of DMAEMA-salt and 8.5mL of methyl methacrylate into a reaction system, continuing stirring for 2h, and performing reduced pressure distillation to remove ethanol and deionized water to obtain an artificial prostate matrix solution;

S2, adding 0.2mL of 10wt% sodium persulfate solution into 20mL of artificial prostate matrix solution, regulating the pH to 8.5, uniformly mixing, transferring into a prostate matrix mould, raising the reaction temperature to 40 ℃, curing for 5 hours, demoulding after curing, washing with deionized water, and vacuum drying to obtain an artificial prostate matrix;

The surface morphology of the sample was observed by scanning electron microscopy (SEM, XL30 FEG, philips), and fig. 1 is an SEM image of the microstructure of the artificial prostate matrix prepared in this example, which is composed of dense network structures.

S3, coating the cytokine coating precursor solution on the inner surface and the outer surface of the artificial prostate precursor prepared in the step S2, and irradiating for 30S under blue-violet light, so as to obtain the artificial prostate tissue induction composite material after the cytokine coating is solidified.

The structural schematic diagram of the artificial prostate tissue inducing composite material prepared in this embodiment is shown in fig. 2, wherein 1 is an artificial prostate substrate and 2 is a cytokine coating.

Example 2

The artificial prostate matrix is prepared by solidifying a prostate matrix material, wherein the preparation raw materials of the artificial prostate matrix material comprise the following components in parts by weight of 8 parts of peptide-metal composite polyether-ether-ketone fibers, 15 parts of DMAEMA-salt and 22 parts of methyl methacrylate;

t1, placing the polyether-ether-ketone fiber in a beaker, sequentially placing acetone, absolute ethyl alcohol and deionized water in an ultrasonic cleaner for cleaning, wherein the power of the ultrasonic cleaner is 500W, the cleaning time is 40min, removing impurities on the surface of the polyether-ether-ketone fiber, and drying to obtain the pretreated polyether-ether-ketone fiber;

T2, soaking the pretreated polyether-ether-ketone fibers prepared in the step T1 in concentrated sulfuric acid, performing ultrasonic treatment at 600W power for 5min, filtering, taking solids, washing with acetone and deionized water in sequence, and drying to obtain sulfonated polyether-ether-ketone fibers;

T3, accurately weighing 3g of sulfonated polyether-ether-ketone fibers, placing the sulfonated polyether-ether-ketone fibers in 90mL of dichloromethane, accurately weighing 4.8g of anhydrous aluminum chloride, placing the anhydrous aluminum chloride in a reaction system, uniformly mixing, accurately weighing 4g of succinic anhydride, dissolving the anhydrous aluminum chloride in 60mL of dichloromethane, introducing nitrogen into the reaction system, slowly dropwise adding succinic anhydride/dichloromethane solution at the speed of 1mL/min, stirring at the speed of 150rpm under the nitrogen atmosphere at the temperature of 40 ℃, cooling the reaction system to room temperature after the reflux reaction is finished for 6h, sequentially carrying out ultrasonic cleaning with 5wt% of sodium hydroxide solution, 5wt% of hydrochloric acid solution, deionized water and acetone at the power of 500W, and carrying out vacuum drying at the temperature of 40 ℃ for 3h to obtain modified polyether-ether-ketone fibers;

1.5g of the modified polyether-ether-ketone fiber prepared in the step T3 is accurately weighed and dispersed in 100mLDMF, 0.3g of zinc chloride is accurately weighed and added into a reaction system, stirring is carried out for full dissolution, 1.35g of dopamine hydrochloride is accurately weighed and dissolved in 22.5mL of ethanol water solution (V _Ethanol:V_{Water and its preparation method} =1:3), the mixture is added into the reaction system, stirring is carried out according to the speed of 350rpm, 0.03g of p-toluenesulfonic acid is added, the reaction temperature is increased to 80 ℃, stirring is carried out for 6 hours, then the reduced pressure distillation is carried out to remove the solvent to prepare Tris buffer solution with the pH of 9.0, 150mL of Tris buffer solution is taken, 150mL of Tris buffer solution is added into the reaction system, the solution is placed into the reaction system, stirring is carried out for 20 hours according to the speed of 500-rpn, filtering is carried out, the precipitate is sequentially washed three times with deionized water, absolute ethyl alcohol and acetone, and vacuum drying is carried out for 12 hours at 40 ℃ to obtain the polydopamine modified polyether-ketone fiber;

Accurately weighing 16g of L-histidine, adding 200mL of tetrahydrofuran into a flask, vacuumizing until no bubbles are generated, continuously introducing flowing nitrogen into a reaction system, stirring at 150rpm, adding 10g of triphosgene, uniformly mixing, raising the reaction temperature to 50 ℃, continuously stirring for 2 hours, adding 14g of triphosgene, continuously stirring for 1 hour, stopping adding after the reaction is gradually clarified, concentrating the reaction system to 20% of the original volume, adding precooled n-hexane into the reaction system for sedimentation, filtering, collecting the sediment, dissolving with 50mL of ethyl acetate for recrystallization treatment, placing in a nitrogen environment, drying, and removing redundant solvent to obtain histidine-NCA;

T6, placing 0.4g of the polydopamine modified polyether-ether-ketone fiber prepared in the step T4 into a beaker, adding 10mL of dichloromethane, fully mixing, adding 1.6g of histidine-NCA prepared in the step T5, vacuumizing a reaction system, introducing argon, stirring and reacting for 24 hours at a speed of 600rpm under an argon atmosphere, filtering to remove dichloromethane, repeatedly washing for three times sequentially with DMF and dichloromethane, placing at 40 ℃, and vacuum drying for 12 hours to obtain the polypeptide composite polyether-ether-ketone fiber;

T7, dispersing 0.2g of the polypeptide composite polyether-ether-ketone fiber prepared in the step T6 in 10mL of absolute ethyl alcohol, accurately weighing 1g of zinc chloride, dissolving in 100mL of deionized water, adding 3mL of zinc chloride into a reaction system, stirring at a speed of 600rpm under a room temperature condition, reacting for 4 hours, transferring the reaction system into a 3500Da dialysis bag, dialyzing with a Tris solution with a pH value of 7.6, and freeze-drying after 24 hours to obtain the peptide-metal composite polyether-ether-ketone fiber;

The cytokine coating is prepared by photocuring cytokine coating precursor solution, and the preparation raw materials of the cytokine coating precursor solution comprise, by weight, 6 parts of aldehyde chitosan powder, 18 parts of methacrylic anhydride, 3 parts of collagen powder, 1 part of TPO (thermoplastic polyolefin elastomer), and 5 parts of BDNF solution;

K1, accurately weighing and dispersing 3g of chitosan in 200mL of deionized water, regulating the pH of a reaction system to 6.5, completely dissolving the chitosan, adding 2.7g of sodium periodate, uniformly mixing, placing the mixture under the condition of room temperature, performing dark reaction for 6 hours, adding ascorbic acid to terminate the reaction until the color of the reaction system is not changed, dialyzing for 2d by using deionized water by using a dialysis bag with the cutoff amount of 3.5kDa after the reaction is completed, and freeze-drying to obtain the hydroformylation chitosan;

K2, dispersing 1.5g of the hydroformylation chitosan prepared in the step K1 in 25mL of DMF solvent, adding 30mL of 3wt% hydrogen peroxide solution, stirring at a speed of 150rpm until the hydroformylation chitosan is completely dissolved, adding 4.5mL of methacrylic anhydride, regulating the pH of a reaction system to 8.5, placing in an ice water bath environment, continuing stirring for reaction for 12h, placing in a dialysis bag with a cutoff of 3.5kDa after the reaction is completed, dialyzing for 2d by deionized water, and freeze-drying to obtain modified chitosan powder;

K3, dissolving 0.75g of collagen in 30mL of 1.2wt% NaCl aqueous solution, adding the modified chitosan powder prepared in the step K2, stirring for reaction at the speed of 200rpm, adding 0.25g of TPO, placing under the condition of 4 ℃ for uniform mixing, adding 1.25mL of 10 mug/mL BDNF solution, and continuing stirring for 3 hours to obtain cytokine coating precursor solution;

S1, placing 2g of the peptide-metal composite polyether-ether-ketone fiber in 30vol percent of ethanol solution of 100mL, performing ultrasonic treatment for 20min under the power of 500W to fully infiltrate the peptide-metal composite polyether-ether-ketone fiber in the ethanol solution, continuously stirring and reacting 3.8g of DMAEMA-salt and 5.5mL of methyl methacrylate for 2h, and then performing reduced pressure distillation to remove ethanol and deionized water to obtain an artificial prostate matrix solution;

S2, adding 15wt% sodium persulfate solution 0.1mL into 20mL of artificial prostate matrix solution, regulating the pH to 8.5, uniformly mixing, transferring into a prostate matrix mould, raising the reaction temperature to 50 ℃, curing for 3 hours, demoulding after curing, washing with deionized water, and vacuum drying to obtain an artificial prostate matrix;

s3, coating the cytokine coating precursor solution on the inner surface and the outer surface of the artificial prostate precursor prepared in the step S2, and irradiating for 45S under blue-violet light, so as to obtain the artificial prostate tissue induction composite material after the cytokine coating is solidified.

Experimental example 3

the artificial prostate matrix is prepared by solidifying a prostate matrix material, wherein the preparation raw materials of the artificial prostate matrix material comprise, by weight, 10 parts of peptide-metal composite polyether-ether-ketone fibers, 15 parts of DMAEMA-salt and 25 parts of methyl methacrylate;

t1, placing the polyether-ether-ketone fibers in a beaker, sequentially placing acetone, absolute ethyl alcohol and deionized water in an ultrasonic cleaner for washing, wherein the power of the ultrasonic cleaner is 500W, the cleaning time is 60min, removing impurities on the surfaces of the polyether-ether-ketone fibers, and drying to obtain pretreated polyether-ether-ketone fibers;

Accurately weighing 5g of sulfonated polyether-ether-ketone fiber, placing the sulfonated polyether-ether-ketone fiber in 100mL of dichloromethane, accurately weighing 5g of anhydrous aluminum chloride, placing the anhydrous aluminum chloride in a reaction system, uniformly mixing, accurately weighing 5g of succinic anhydride, dissolving the anhydrous aluminum chloride in 50mL of dichloromethane, introducing nitrogen into the reaction system, slowly dropwise adding succinic anhydride/dichloromethane solution according to the speed of 1mL/min, under the nitrogen atmosphere, raising the temperature to 40 ℃, stirring according to the speed of 150rpm, carrying out reflux reaction for 5h, cooling the reaction system to room temperature after the reaction is finished, sequentially carrying out ultrasonic cleaning by 5wt% of sodium hydroxide solution, 5wt% of hydrochloric acid solution, deionized water and acetone under the power of 500W, and carrying out vacuum drying for 3h at the temperature of 40 ℃ to obtain modified polyether-ether-ketone fiber;

And T4, accurately weighing 2g of the modified polyether-ether-ketone fiber prepared in the step T3, dispersing in 200mLDMF, accurately weighing 0.3g of zinc chloride, adding the zinc chloride into a reaction system, stirring for full dissolution, accurately weighing 1.4g of dopamine hydrochloride, dissolving in 28mL of ethanol water solution (V _Ethanol:V_{Water and its preparation method} =1:3), adding the solution into the reaction system, stirring at the speed of 330rpm, adding 0.03g of p-toluenesulfonic acid, raising the reaction temperature to 90 ℃, continuously stirring for 4h, distilling under reduced pressure to remove a solvent, preparing a Tris buffer solution with the pH of 8.5, taking 200mL of the Tris buffer solution, adding the solution into the reaction system, stirring for reacting for 28h at the speed of 550rpn, filtering, sequentially and repeatedly washing the precipitate with deionized water, absolute ethyl alcohol and acetone for three times, and drying in vacuum for 12h at the temperature of 40 ℃ to obtain the polydopamine modified polyether-ketone fiber;

T5, accurately weighing 10g of L-histidine, adding 150mL of tetrahydrofuran, vacuumizing until no bubbles are generated, continuously introducing flowing nitrogen into a reaction system, stirring at 150rpm, adding 7g of triphosgene, uniformly mixing, raising the reaction temperature to 60 ℃, continuously stirring for reacting for 1.5 hours, adding 7g of triphosgene, continuously stirring for reacting for 1 hour, stopping adding after the reaction is gradually clarified, concentrating the reaction system to 20% of the original volume, adding pre-cooled n-hexane into the reaction system for sedimentation, filtering, collecting the sediment, dissolving with 50mL of ethyl acetate for recrystallization, placing in a nitrogen environment, drying, and removing redundant solvent to obtain histidine-NCA;

T6, placing 0.9g of the polydopamine modified polyether-ether-ketone fiber prepared in the step T4 into a beaker, adding 20mL of dichloromethane, fully mixing, adding 3.2g of histidine-NCA prepared in the step T5, vacuumizing a reaction system, introducing argon, stirring and reacting for 30 hours at a speed of 500rpm under an argon atmosphere, performing suction filtration, removing dichloromethane, repeatedly washing for three times sequentially with DMF and dichloromethane, placing at 40 ℃, and performing vacuum drying for 12 hours to obtain the polypeptide composite polyether-ether-ketone fiber;

T7, dispersing 0.1g of the polypeptide composite polyether-ether-ketone fiber prepared in the step T6 in 10mL of absolute ethyl alcohol, accurately weighing 1g of zinc chloride, dissolving in 100mL of deionized water, adding 20mL of zinc chloride into a reaction system, stirring at a speed of 400rpm under the condition of room temperature, reacting for 6 hours, transferring the reaction system into a 3500Da dialysis bag, dialyzing with a Tris solution with a pH value of 7.6, and freeze-drying after 24 hours to obtain the peptide-metal composite polyether-ether-ketone fiber;

The cytokine coating is prepared by photocuring cytokine coating precursor solution, and the preparation raw materials of the cytokine coating precursor solution comprise, by weight, 6 parts of aldehyde chitosan powder, 16 parts of methacrylic anhydride, 4 parts of collagen powder, 0.9 part of TPO (thermoplastic polyolefin elastomer) and 5 parts of BDNF solution;

K1, accurately weighing 4g of chitosan, dispersing the chitosan in 200mL of deionized water, regulating the pH of a reaction system to 6, completely dissolving the chitosan, adding 3.5g of sodium periodate, uniformly mixing, placing the mixture under the condition of room temperature, performing dark reaction for 7 hours, adding ascorbic acid to terminate the reaction until the color of the reaction system is not changed, dialyzing the mixture for 2d by using deionized water by using a dialysis bag with the retention amount of 3.5kDa after the reaction is completed, and freeze-drying to obtain the hydroformylation chitosan;

K2, dispersing 1.5g of the hydroformylation chitosan prepared in the step K1 in 30mL of DMF solvent, adding 20mL of 3wt% hydrogen peroxide solution, stirring at a speed of 150rpm until the hydroformylation chitosan is completely dissolved, adding 4mL of methacrylic anhydride, adjusting the pH of a reaction system to 8, placing in an ice water bath environment, continuing stirring for reaction for 12h, placing in a dialysis bag with a retention amount of 3.5kDa after the reaction is completed, dialyzing for 2d with deionized water, and freeze-drying to obtain modified chitosan powder;

K3, dissolving 1g of collagen in 50mL of 1.1wt% NaCl aqueous solution, adding the modified chitosan powder prepared in the step K2, stirring for reaction at the speed of 200rpm, adding 0.225g of TPO, placing the mixture under the condition of 4 ℃ for uniform mixing, adding 1.25mL of 10 mug/mL BDNF solution, and continuing stirring for 2.5 hours to obtain cytokine coating precursor solution;

S1, placing 5g of the peptide-metal composite polyether-ether-ketone fiber in 30vol% of 200mL of ethanol solution, performing ultrasonic treatment for 20min under 500W power, fully soaking the peptide-metal composite polyether-ether-ketone fiber in the ethanol solution, stirring at the speed of 250rpm, reacting for 1h, adding 7.5g of DMAEMA-salt and 12.5mL of methyl methacrylate into a reaction system, continuing stirring for reacting for 3h, and then performing reduced pressure distillation to remove ethanol and deionized water to obtain an artificial prostate matrix solution;

S2, adding 20mL of artificial prostate matrix solution into 0.1mL of 20wt% sodium persulfate solution, regulating the pH to 8.5, uniformly mixing, transferring into a prostate matrix mould, raising the reaction temperature to 45 ℃, curing for 4 hours, demoulding after curing, washing with deionized water, and vacuum drying to obtain an artificial prostate matrix;

S3, coating the cytokine coating precursor solution on the inner surface and the outer surface of the artificial prostate precursor prepared in the step S2, and irradiating for 60S under blue-violet light, so as to obtain the artificial prostate tissue induction composite material after the cytokine coating is solidified.

Comparative example 1

This comparative example provides an artificial prostate composite material and a method for preparing the same, which are different from example 1 only in that the raw materials for preparing the artificial prostate matrix material do not include peptide-metal composite polyether-ether-ketone fibers, and are replaced by polyether-ether-ketone fibers with the same mass fraction, and the rest components, component contents and preparation method are the same as example 1.

Comparative example 2

This comparative example provides an artificial prostate composite material and a method for preparing the same, which are different from example 1 only in that DMAEMA-salt is not included in the raw materials for preparing the artificial prostate matrix material, and the remaining components, component contents, and preparation method are the same as example 1.

Comparative example 3

The comparison provides an artificial prostate composite material and a preparation method thereof, which are different from the preparation method of the embodiment 1 only in that the preparation method of the peptide-metal composite polyether-ether-ketone fiber does not comprise the step T4, that is, the surface of the polyether-ether-ketone fiber is not subjected to polydopamine coating treatment, and the artificial prostate composite material is only the peptide-metal coated polyether-ether-ketone fiber, and the rest components, the content of the components and the preparation method are the same as the embodiment 1.

Comparative example 4

This comparative example provides an artificial prostate composite material and a method for preparing the same, which is different from example 1 only in that the chitosan is replaced with hyaluronic acid in the same mass ratio in the method for preparing the cytokine coating precursor solution, and the rest components, component contents and preparation method are the same as example 1.

Experimental example 1

The experimental example is used for measuring the mechanical properties of the prostate precursor matrixes prepared in the examples 1-3 and the comparative examples 1-3, preparing artificial prostate matrix samples according to the size of 50X 10X 5mm after solidifying the artificial prostate matrix solutions prepared in the examples and the comparative examples 1-3, placing the samples on an AGX electronic universal material tester by adopting a three-point bending method specified by ISO 14125, evaluating the bending properties of the samples, and setting parameters of the AGX electronic universal material tester, wherein the loading speed of a bending strength test is 5mm/min and the loading speed of a bending modulus test is 1mm/min;

Fig. 3 is a graph showing the mechanical properties of the prostate precursor matrix prepared in examples 1-3 and comparative examples 1-3, wherein the artificial prostate matrix prepared in example 1-3 has higher bending strength and bending modulus, the mechanical properties of comparative example 1 are the lowest, and then comparative example 2, the polyether-ether-ketone fiber is not modified in the technical scheme in comparative example 1, the surface of the polyether-ether-ketone fiber has stronger hydrophobic property, the compatibility with polyacrylate materials is poor, aggregation easily occurs in the process of preparing the artificial prostate matrix material, the polyether-ether-ketone fiber is unevenly dispersed in the matrix material, the mechanical properties are reduced, the technical scheme in comparative example 2 does not adopt DMAEMA-salt, the sulfonic acid group has stronger polarity generally, can generate strong hydrogen bonding effect with surrounding molecules, and is favorable for improving the polarity and stability of polymers, in addition, the sulfonic acid group can possibly bring about the property of water solubility and crosslinking property among reinforced material molecules, the introduction of the DMAEMA-salt not only enhances the density of a crosslinked network, but also improves the mechanical properties of the dopamine-ether-ketone fiber by introducing flexible structure, thereby improving the mechanical properties of the modified polyether-ketone fiber, and reducing the brittle-ketone-containing material has the mechanical properties by the mechanical properties, and improving the mechanical properties of the brittle-free-prostatic-fiber-containing material.

Experimental example 2

The experimental example is to measure the release performance of the nerve cell trophic factor of the artificial prostate tissue inducing composite material prepared in the example 1 and the comparative examples 1-4, the artificial prostate matrix is prepared according to the sample size described in the experimental example 1, 5mL of cytokine coating precursor solution is coated on the surface of the artificial prostate tissue inducing composite material, after photo-curing, the artificial prostate tissue inducing composite material sample is obtained, the test is placed in a release bottle, 15mL of PBS buffer solution is added, the release bottle is placed on a shaking table at 37 ℃ and is oscillated at the speed of 120rpm, the release solution is sucked every 12h, and then the same amount of PBS buffer solution is added for supplementing, the obtained release is measured for BDNF content by an ELISA analysis method, and the ELISA kit is brain-derived nerve trophic factor (BDNF) detection kit (cloud clone (Beijing biotechnology Co., ltd., product number SCA011 Hu).

FIG. 4 is a graph showing the results of the release performance of BDNF of the artificial prostate tissue-inducing composite material prepared in example 1 and comparative examples 1 to 4, wherein the cytokine coating prepared in examples 1 to 4 of the present invention is in a stable state for BDNF release, the release amount of the cytokine coating prepared in comparative example 2 reaches 4564.1pg/mL at 72h, and the release amount of the cytokine coating prepared in comparative example 4 reaches 5326.5pg/mL at 48h, which indicates that the cytokine coating disintegrates in the release solution, and the stability of the cytokine coatings of the artificial prostate tissue-inducing composite material prepared in comparative examples 2 and 3 is poor.

The experimental example is to measure the long-term release effect of the nerve cell trophic factor of the artificial prostate tissue induction composite material prepared in the example 1 and the comparative example 1 and 3, the artificial prostate matrix is prepared according to the sample size described in the experimental example 1, 5mL of cytokine coating precursor solution is coated on the surface of the artificial prostate tissue induction composite material, after photocuring, an artificial prostate tissue induction composite material sample is obtained, the test is placed in a release bottle, 15mL of PBS buffer is added, the release bottle is placed on a shaking table at 37 ℃ and is oscillated at the speed of 120rpm, sampling is carried out according to the time point, then equal amount of PBS buffer is added for supplementing, the content of BDNF is measured by an ELISA analysis method for the obtained release, and the cumulative release rate (%) is calculated, and the ELISA kit is a brain-derived nerve trophic factor (BDNF) detection kit (cloud clone (Beijing) biotechnology Co., ltd, SCA011 Hu).

Fig. 5 is a graph showing the long-term slow release effect of the artificial prostate tissue inducing composite material prepared in example 1 and comparative examples 1 and 3, wherein the artificial prostate tissue inducing composite material prepared in example 1 can reach 93.34% of BDNF release rate within 180 days, while the release of comparative example 1 is stopped between 60 days and 90 days, the release of comparative example 3 is stopped between 90 days and 120 days, the release of the comparative example 1 and the release of comparative example 2 are caused by the falling of cell coating, the structure of the artificial prostate tissue inducing composite material is changed, the release amount of the artificial prostate tissue inducing composite material is stopped, the comparative example 1 adopts PEEK as a filling material, the dispersibility of PEEK fibers in an acrylic resin is poor, the PEEK fibers in an aqueous environment is poor, the separation from the acrylic resin is easy to occur, the internal stress is increased, the prostatic matrix is unstable, the coated person is separated, the compatibility of the peptide-metal modified fiber is obviously increased in comparative example 2, the PEEK is easy to be influenced by the interaction in a long-term process through long-term soaking in an aqueous environment, and the interaction between the peptide-metal and PEEK is easy to be affected by the interaction in a long-term process.

Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made hereto without departing from the spirit and principles of the present invention.

The invention and its embodiments have been described above with no limitation, and the invention is illustrated in the figures of the accompanying drawings as one of its embodiments, without limitation in practice. In summary, those skilled in the art, having benefit of this disclosure, will appreciate that the invention can be practiced without the specific details disclosed herein.

Claims

1. An artificial prostate tissue induction composite material is characterized in that the composite material comprises an artificial prostate basal body and a cytokine coating;

The artificial prostate matrix is prepared by solidifying a prostate matrix material, wherein the preparation raw materials of the artificial prostate matrix material comprise, by weight, 5-10 parts of peptide-metal composite polyether-ether-ketone fibers, 12-15 parts of 3- [ N, N-dimethyl- [2- (2-methylpropan-2-enoyloxy) ethyl ] ammonium ] propane-1-sulfonic acid inner salt and 20-25 parts of methyl methacrylate;

The cytokine coating is prepared by photocuring a cytokine coating precursor solution, and the preparation raw materials of the cytokine coating precursor solution comprise, by weight, 5-8 parts of aldehyde chitosan powder, 14-18 parts of methacrylic anhydride, 3-5 parts of collagen powder, 0.8-1 part of 2,4, 6-trimethylbenzoyl-diphenyl oxide and 5-6 parts of BDNF solution;

the BDNF solution is a solution of BDNF dissolved in deionized water, and the mass concentration is 10 mug/mL.

2. The artificial prostate tissue inducing composite of claim 1, further comprising a signal acquisition module, a signal control module, and a treatment module.

3. The artificial prostate tissue inducing composite material of claim 2, wherein said signal acquisition module acquires bladder urethra pressure state, urine outflow and overflow state and transmits data to signal control module, said signal control module controls treatment module to perform continuous discharge stimulation to achieve the effects of regulating bladder urethra sensation and relieving urinary frequency and incontinence.

4. The method for preparing the artificial prostate tissue inducing composite material according to any one of claims 1 to 3, which is characterized by comprising the following steps:

S1, placing the peptide-metal composite polyether-ether-ketone fiber in an ethanol solution, stirring at a speed of 200-250rpm, fully dispersing for 1-2 hours, adding DMAEMA-salt and methyl methacrylate into a reaction system, continuously stirring for 2-3 hours, and then distilling under reduced pressure to remove ethanol and deionized water to obtain an artificial prostate matrix solution, wherein the mass concentration of the peptide-metal composite polyether-ether-ketone fiber in the ethanol solution is 10-25g/L;

S2, adding the sodium persulfate solution into the artificial prostate matrix solution prepared in the step S1, regulating the pH value to 8.5, uniformly mixing, transferring into a prostate matrix mould, increasing the reaction temperature to 40-50 ℃, curing for 3-5 hours, demoulding after curing, washing with deionized water, and vacuum drying to obtain an artificial prostate matrix, wherein the mass fraction of sodium persulfate in the sodium persulfate solution is 10-20%, and the addition volume of the sodium persulfate solution is 0.5-1% of the volume of the artificial prostate matrix solution;

S3, coating the cytokine coating precursor solution on the inner surface and the outer surface of the artificial prostate precursor prepared in the step S2, irradiating for 30-60S under blue-violet light, and curing the cytokine coating to obtain the artificial prostate tissue induction composite material.

5. The method for preparing the artificial prostate tissue inducing composite material according to claim 4, wherein the method for preparing the peptide-metal composite polyether-ether-ketone fiber comprises the following steps:

And T7, dispersing the polypeptide composite polyether-ether-ketone fiber prepared in the step T6 in absolute ethyl alcohol, adding zinc chloride, stirring at the speed of 400-500rpm under the condition of room temperature, reacting for 4-6h, dialyzing with 3500Da dialysis bag with Tris buffer solution for 24h, and freeze-drying to obtain the peptide-metal composite polyether-ether-ketone fiber.

6. The preparation method of the artificial prostate tissue induction composite material according to claim 5, wherein in the step T3, the mass concentration of the sulfonated polyether ether ketone fiber in methylene dichloride is 25-50g/L, the mass concentration of the succinic anhydride in methylene dichloride is 0.065-0.1g/mL, the mass ratio of the sulfonated polyether ether ketone fiber to the succinic anhydride is 2:1.5-2.5, and the mass ratio of the sulfonated polyether ether ketone fiber to the anhydrous aluminum chloride is 1:1-1.2;

In the step T4, the mass concentration of the modified polyether-ether-ketone fibers in DMF is 10-15g/L, the addition amount of zinc chloride is 10-20% of the mass of the modified polyether-ether-ketone fibers, the dopamine solution is a solution of dopamine dissolved in an ethanol water solution (V _Ethanol:V_{Water and its preparation method} =1:3), the mass concentration of the dopamine in the ethanol water solution is 40-60g/L, the mass ratio of the dopamine to the modified polyether-ether-ketone fibers is 1:0.7-0.9, in the step T4, the addition amount of the p-toluenesulfonic acid is 1-2% of the mass of the modified polyether-ether-ketone fibers, and the volume ratio of the Tris buffer solution to the DMF solvent is 1-1.5:1.

7. The method for preparing an artificial prostate tissue inducing composite according to claim 6, wherein in the step T5, the mass concentration of the L-histidine in tetrahydrofuran is 60-80g/L, and the mass ratio between the L-histidine and triphosgene is 1:1.2-1.5;

In the step T6, the mass concentration of the polydopamine modified polyether-ether-ketone fiber in dichloromethane is 40-50g/L, and the mass ratio of the polydopamine modified polyether-ether-ketone fiber to histidine-NCA is 1:3-4;

In the step T7, the mass concentration of the polypeptide composite polyether-ether-ketone fiber in absolute ethyl alcohol is 10-15g/L, and the addition mass of the zinc chloride is 15-20% of the mass of the polypeptide composite polyether-ether-ketone fiber.

8. The method for preparing an artificial prostate tissue inducing composite according to claim 7, wherein the method for preparing a cytokine coating precursor solution comprises the steps of:

K2, dispersing the hydroformylation chitosan prepared in the step K1 in a DMF solvent, adding hydrogen peroxide, stirring until the hydroformylation chitosan is completely dissolved at a speed of 150rpm, adding methacrylic anhydride, regulating the pH of a reaction system to 8-9, placing in an ice water bath environment, continuously stirring for reaction for 12 hours, placing in a dialysis bag after the reaction is finished, dialyzing for 2d with deionized water, and freeze-drying to obtain modified chitosan powder;

And K3, dissolving collagen in NaCl aqueous solution, adding the modified chitosan powder prepared in the step K2, stirring for reaction at the speed of 200rpm, adding 2,4, 6-trimethylbenzoyl-diphenyl phosphine oxide, placing the mixture under the condition of 4 ℃ for uniform mixing, adding BDNF solution, and continuously stirring for 2-3 hours to obtain cytokine coating precursor solution.

9. The method for preparing the artificial prostate tissue inducing composite according to claim 8, wherein in the step K1, the mass concentration of the chitosan in deionized water is 15-25g/L, and the mass ratio of the chitosan to the sodium periodate is 10:8-9.

10. The method for preparing the artificial prostate tissue inducing composite according to claim 9, wherein in the step K2, the mass concentration of the aldehyde chitosan in DMF solvent is 40-60g/L, in the step K3, the mass fraction of the NaCl aqueous solution is 1% -1.2%, and the mass concentration of the collagen in the NaCl aqueous solution is 20-25g/L.